Citations

Clear

2511 citation(s) found for "Yang, Yu".

Does Marital Status Impact Survival and Quality of Life in Patients with Non-Small Cell Lung Cancer? Observations from the Mayo Clinic Lung Cancer Cohort
Jatoi, Aminah , Novotny, Paul J. , Cassivi, Stephen D. , Clark, Matthew M. , Midthun, David E. , Sloan, Jeff A. , Patten, Christi A. , Yang, Ping

Mayo Clinic

The Oncologist | December 28, 2007 | Volume: 12 | Issue: 12 | Pages: 1456-1463

10.1634/theoncologist.12-12-1456 | PMID 18165623 Get It

Abstract Purpose. Previous studies have found that marriage is associated with longer survival and better quality of life among lung cancer patients. The present study used the Mayo Clinic Lung Cancer Cohort to re-examine this issue. Methods. In total, 5,898 non-small cell lung cancer (NSCLC) patients, who had available information on marital status and who had been enrolled in the Mayo Clinic Lung Cancer Cohort (MCLCC), were the focus of this study. Patients had extensive baseline and follow-up data on cancer stage, cancer treatment, and prognostic factors. All patients had been followed within the MCLCC with at least annual confirmation of vital status and patient-reported quality of life (the Lung Cancer Symptom Scale and the Linear Analogue Scales of Assessment). Results. The numbers of patients who were married, single, divorced, and widowed at the time of cancer diagnosis were 4,457 (76%), 265 (4%), 440 (7%), and 736 (12%), respectively. No statistically significant difference in survival was observed among these four groups, even after adjusting for a variety of prognostic factors, such as age, gender, and tumor stage. However, exploratory analyses suggested that widowed and divorced patients received less aggressive cancer therapy, and certain patient subgroups, such as stage IA widowed patients, had a shorter survival. Divorced patients reported greater financial concerns, and married and widowed patients reported greater spirituality and better social support. Conclusion. This study did not observe differences in survival or quality of life based on marital status at the time of diagnosis of NSCLC, but subgroup analyses appear to suggest findings worthy of further exploration.
The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans
Lavi, Shahar , Prasad, Abhiram , Mathew, Verghese, Barsness, Gregory W. , Rihal, Charanjit S. , Lerman, Lilach O. , Yang, Eric H. , Rihal, Charanjit S. , Lerman, Amir , Prasad, Abhiram

Mayo Clinic

Hypertension | December 18, 2007 | Volume: 51 | Issue: 1 | Pages: 127-133

10.1161/hypertensionaha.107.099986 | PMID 18086957 Get It

In vitro and animal studies suggest that oxidative stress is associated with endothelial dysfunction. We tested whether local oxidative stress and nitric oxide (NO) bioavailability in the coronary circulation is associated with coronary endothelial dysfunction in humans. Blood samples were obtained simultaneously from the left main coronary artery and the coronary sinus for measurement of F2-isoprostanes, myeloperoxidase, nitrotyrosine, and superoxide dismutase in 20 patients without significant coronary disease. Afterward, coronary blood flow and the vascular response to intracoronary acetylcholine and N G -monomethyl- L -arginine (L-NMMA) were assessed. The gradient of isoprostanes between the arterial levels and coronary sinus correlated with the change in coronary artery diameter in response to acetylcholine ( r =−0.79, P <0.0001). Isoprostanes net production across the left anterior descending artery territory correlated with a decrease in superoxide dismutase activity ( r =0.66, P =0.002) and decrease in coronary artery diameter in response to L-NMMA (r s =0.48, P <0.05). Myeloperoxidase and nitrotyrosine gradients were similar in patients with endothelial dysfunction and controls. The effect of L-NMMA was similar in both groups. We conclude that coronary endothelial dysfunction in humans is characterized by local enhancement of oxidative stress without a decrease in basal NO release. This study supports the hypothesis that local oxidative stress has a role in reduction of NO bioavailability in humans with coronary endothelial dysfunction.
Cryopreservation of Human Nasal Ciliated Epithelium
McCaffrey, Thomas V., Kern, Eugene B. , Yang, Bin

Mayo Clinic

American Journal of Rhinology | October 7, 2007 | Volume: 10 | Issue: 5 | Pages: 291-298

10.2500/105065896782159684 Get It

The purpose of this study was to compare the effects on human nasal cilia of various freezing and thawing methods in order to determine a reliable method of cryopreservation. Ten samples each were preserved by a slow freezing and a fast freezing method. All samples were stored in liquid nitrogen (–196°C) for 1 week. The frozen samples were thawed by one of two methods: 1) rapid thawing—37°C water bath for 3–4 minutes; and 2) slow thawing—room temperature for 15 minutes. Prefreeze and postthaw ciliary beat frequency (CBF) was measured. The slow freezing and fast thawing method (SFFT) resulted in the best viability. An additional 10 samples preserved using the SFFT method stored at –70°C to –90°C did not retain ciliary function. Thirty ciliated samples preserved by the SFFT method were examined after freezing in liquid nitrogen (–196°C) for 1 week, 2 weeks, and 1 month. There was no significant decrease in CBF after cryopreservation at –196°C for 1 week or 2 weeks (P> 0.05). As the storage time increased to 1 month, postthaw CBF decreased 7.25 ± 0.87% when compared to the prefreeze CBF (P < 0.05). We conclude that human nasal cilia preserved by SFFT at –196°C retain activity for up to 1 month.
GLIOGENE—an International Consortium to Understand Familial Glioma
Malmer, Beatrice, Adatto, Phyllis, Armstrong, Georgina , Barnholtz‐Sloan, Jill S. , Bernstein, Jonine L. , Claus, Elizabeth B. , Davis, Faith G., Houlston, Richard S. , Jenkins, Robert B. , Johansen, Christoffer , Lai, Rose , McCarthy, Bridget J., Nielsen, Hanne Melgaard, Olson, Sara H. , Sadetzki, Siegal, Shete, Sanjay , Wrensch, Margaret , Bondy, Melissa L. , Armstrong, Georgina , Il’yasova, Dora , Lau, Ching C. , Wiklund, Fredrik E. , Yang, Ping , Houlston, Richard S , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 13, 2007 | Volume: 16 | Issue: 9 | Pages: 1730-1734

10.1158/1055-9965.epi-07-0081 | PMID 17855690 Get It

AbstractEvidence for familial aggregation of glioma has been documented in both case-control and cohort studies and occurs apart from the well-described rare inherited genetic syndromes involving glioma: neurofibromatosis type 1 and 2, tuberous sclerosis, Turcot's syndrome, and Li-Fraumeni syndrome. Nonsyndromic glioma families have been studied but no genes have been identified in the two published linkage studies of familial glioma probably due to the small number of families. Because glioma is a rare but devastating cancer, and a family history of glioma has been observed in ∼5% of the cases, we initiated an international consortium to identify glioma families not affected by syndromes to better understand the inherited factors related to this disease. The international consortium GLIOGENE is an acronym for “glioma gene” and includes 15 research groups in North America, Europe, and Israel to study familial glioma. The overarching goal is to characterize genes in glioma families using a genome-wide single-nucleotide polymorphism approach and conducting linkage analysis to identify new genomic regions or loci that could harbor genes important for gliomagenesis. Here, we review the rationale for studying familial glioma and our proposed strategy for the GLIOGENE study. (Cancer Epidemiol Biomarkers Prev 2007;16(9):1730–4)
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25− T cells
Yang, Zhi‐Zhang, Novak, Anne J. , Ziesmer, Steven C., Ansell, Stephen M. , Witzig, Thomas E.

Mayo Clinic

Blood | July 6, 2007 | Volume: 110 | Issue: 7 | Pages: 2537-2544

10.1182/blood-2007-03-082578 | PMID 17615291 Get It

Foxp3 expression was initially thought to be restricted to the CD4+CD25+ regulatory T-cell population. However, recent studies suggest that forkhead box P3 (Foxp3) is expressed in CD4+CD25− T cells in aged mice. In the present study in B-cell non-Hodgkin lymphoma (NHL), we found that a subset of intratumoral but not peripheral blood CD4+CD25− T cells, comprising about 15% of intratumoral CD4+ T cells, express Foxp3 and are capable of suppressing the proliferation of autologous infiltrating CD8+ T cells. In vitro activation with OKT3/anti-CD28 antibody (Ab) or dendritic cells (DCs) induced Foxp3 expression in a subset of these CD4+CD25−Foxp3− T cells. We found that the presence of lymphoma B cells during activation augmented activation-induced Foxp3 expression in CD4+CD25− T cells. We also found that CD70+ lymphoma B cells significantly contributed to the activation-induced Foxp3 expression in intratumoral CD4+CD25− T cells. Furthermore, the blockade of CD27-CD70 interaction by anti-CD70 Ab abrogated lymphoma B-cell–mediated induction of Foxp3 expression in intratumoral CD4+CD25− T cells. Taken together, these studies reveal a novel role for NHL B cells in the development of intratumoral regulatory T cells.
EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity
Vikis, Haris G., Sato, Mitsuo , James, Michael A. , Wang, Daolong, Wang, Yian , Wang, Min , Jia, Dongmei , Liu, Yan , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Seminara, Daniela, Viswanathan, Avinash, Govindan, Ramaswamy , Anderson, Marshall W., You, Ming , Amos, Christopher I. , Andrade, Mariza de , Yang, Ping , Minna, John Dorrance , Wilson, Richard K , Pinney, Susan M , Govindan, Ramaswamy

Mayo Clinic

Cancer Research | May 18, 2007 | Volume: 67 | Issue: 10 | Pages: 4665-4670

10.1158/0008-5472.can-07-0217 | PMID 17510392 Get It

Abstract The use of tyrosine kinase inhibitors (TKI) has yielded great success in treatment of lung adenocarcinomas. However, patients who develop resistance to TKI treatment often acquire a somatic resistance mutation (T790M) located in the catalytic cleft of the epidermal growth factor receptor (EGFR) enzyme. Recently, a report describing EGFR-T790M as a germ-line mutation suggested that this mutation may be associated with inherited susceptibility to lung cancer. Contrary to previous reports, our analysis indicates that the T790M mutation confers increased Y992 and Y1068 phosphorylation levels. In a human bronchial epithelial cell line, overexpression of EGFR-T790M displayed a growth advantage over wild-type (WT) EGFR. We also screened 237 lung cancer family probands, in addition to 45 bronchoalveolar tumors, and found that none of them contained the EGFR-T790M mutation. Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer. [Cancer Res 2007;67(10):4665–70]
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Yang, Lin , Grogan, Patrick T., Kitange, Gaspar J. , Carlson, Brett L. , Dinca, Eduard B., James, C. David , Sarkaria, Jann N. , Schroeder, Mark A. , Galanis, Evanthia , Giannini, Caterina , Wu, Wenting

Mayo Clinic

Molecular Cancer Therapeutics | March 15, 2007 | Volume: 6 | Issue: 3 | Pages: 1167-1174

10.1158/1535-7163.mct-06-0691 | PMID 17363510 Get It

Abstract In the current study, we examined a panel of serially passaged glioblastoma xenografts, in the context of an intracranial tumor therapy response model, to identify associations between glioblastoma molecular characteristics and tumor sensitivity to the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib. From an initial evaluation of 11 distinct glioblastoma xenografts, two erlotinib-sensitive tumors were identified, each having amplified EGFR and expressing wild-type PTEN. One of these tumors expressed truncated EGFRvIII, whereas the other expressed full-length EGFR. Subsequent cDNA sequence analysis revealed the latter tumor as expressing an EGFR sequence variant with arginine, rather than leucine, at amino acid position 62; this was the only EGFR sequence variant identified among the 11 xenografts, other than the aforementioned vIII sequence variant. EGFR cDNAs were then examined from 12 more xenografts to determine whether additional missense sequence alterations were evident, and this analysis revealed one such case, expressing threonine, rather than alanine, at amino acid position 289 of the extracellular domain. This glioblastoma was also amplified for EGFR, but did not display significant erlotinib sensitivity, presumably due to its lacking PTEN expression. In total, our study identified two erlotinib-sensitive glioblastoma xenografts, with the common molecular characteristics shared by each being the expression of wild-type PTEN in combination with the expression of amplified and aberrant EGFR. [Mol Cancer Ther 2007;6(3):1167–74]
Actin-binding Proteins Coronin-1a and IBA-1 are Effective Microglial Markers for Immunohistochemistry
Ahmed, Zeshan, Shaw, Gerry , Sharma, Ved P. , Yang, Cui , Dickson, Dennis W. , McGowan, Eileen , Dickson, Dennis W

Mayo Clinic

Journal of Histochemistry & Cytochemistry | March 6, 2007 | Volume: 55 | Issue: 7 | Pages: 687-700

10.1369/jhc.6a7156.2007 | PMID 17341475 Get It

This study identifies the actin-binding protein, coronin-1a, as a novel and effective immunohistochemical marker for microglia in both cell cultures and in formaldehyde-fixed, paraffin-embedded tissue. Antibodies to coronin-1a effectively immunostained microglia in human, monkey, horse, rat, and mouse tissues, even in tissues stored for long periods of time. The identity of coronin-1a-immunoreactive cells as microglia was confirmed using double immunolabeling with cell type-specific markers as well as by morphological features and the distribution of immunoreactive cells. These properties are shared by another actin-binding protein, IBA-1. Unlike IBA-1, coronin-1a immunoreactivity was also detected in lymphocytes and certain other hematopoietic cells. The results indicate that both coronin-1a and IBA-1 are robust markers for microglia that can be used in routinely processed tissue of humans and animals. Because both coronin-1a and IBA-1 are actin-binding proteins that play a role in rearrangement of the membrane cytoskeleton, it suggests that these proteins are critical to dynamic properties of microglia.
Gene-Expression Profiling in Lung Cancer: Still Early Days
Sun, Zhifu , Yang, Ping , Sun, Zhifu

Mayo Clinic

Pharmacogenomics | February 7, 2007 | Volume: 8 | Issue: 2 | Pages: 129-132

10.2217/14622416.8.2.129 | PMID 17286534 Get It

Identification of a Novel Tumor Suppressor Gene p34 on Human Chromosome 6q25.1
Vikis, Haris G., Wang, Yian , Jia, Dongmei , Wang, Daolong, Bailey‐Wilson, Joan E. , Pinney, Susan M. , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F., Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Seminara, Daniela, Liu, Yan , Viswanathan, Avinash, Govindan, Ramaswamy , Anderson, Marshall W., You, Ming , Wang, Min , Bierut, Laura Jean , Amos, Christopher I. , Andrade, Mariza de , Yang, Ping , Gazdar, Adi, Minna, John Dorrance , Wilson, Richard K , Pinney, Susan M , Govindan, Ramaswamy

Mayo Clinic

Cancer Research | January 8, 2007 | Volume: 67 | Issue: 1 | Pages: 93-99

10.1158/0008-5472.can-06-2723 | PMID 17210687 Get It

Abstract In this study, we observed loss of heterozygosity (LOH) in human chromosomal fragment 6q25.1 in sporadic lung cancer patients. LOH was observed in 65% of the 26 lung tumors examined and was narrowed down to a 2.2-Mb region. Single-nucleotide polymorphism (SNP) analysis of genes located within this region identified a candidate gene, termed p34. This gene, also designated as ZC3H12D, C6orf95, FLJ46041, or dJ281H8.1, carries an A/G nonsynonymous SNP at codon 106, which alters the amino acid from lysine to arginine. Nearly 73% of heterozygous lung cancer tissues with LOH and the A/G SNP also exhibited loss of the A allele. In vitro clonogenic and in vivo nude mouse studies showed that overexpression of the A allele exerts tumor suppressor function compared with the G allele. p34 is located within a recently mapped human lung cancer susceptibility locus, and association of the p34 A/G SNP was tested among these families. No significant association between the less frequent G allele and lung cancer susceptibility was found. Our results suggest that p34 may be a novel tumor suppressor gene involved in sporadic lung cancer but it seems not to be the candidate familial lung cancer susceptibility gene linked to chromosomal region 6q23-25. [Cancer Res 2007;67(1):93–9]